The impacts of the COVID-19 pandemic on treatment-resistant schizophrenia patients having followed virtual reality therapy or cognitive behavioural therapy: a content analysis

References

• Šimunović Filipčić I, Filipčić I. Schizophrenia and physical comorbidity. Psychiatr Danub. 2018;30(4):152–157.
   PubMedGoogle Scholar
• Nucifora FC Jr, Woznica E, Lee BJ, et al. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257.
   PubMed Web of Science ®Google Scholar
• Alegría M, NeMoyer A, Falgàs Bagué I, et al. Social determinants of mental health: where we are and where we need to go. Curr Psychiatry Rep. 2018;20(11):95.
   PubMed Web of Science ®Google Scholar
• Saladino V, Algeri D, Auriemma V. The psychological and social impact of covid-19: new perspectives of Well-Being. Front Psychol. 2020;11:577684.
   PubMed Web of Science ®Google Scholar
• Wu T, Jia X, Shi H, et al. Prevalence of mental health problems during the COVID-19 pandemic: a systematic review and meta-analysis. J Affect Disord. 2021;281:91–98.
   PubMed Web of Science ®Google Scholar
• Caqueo-Urízar A, Urzúa A, Ponce-Correa F, et al. Psychosocial effects of the COVID-19 pandemic on patients with schizophrenia and their caregivers. Front Psychol. 2021;12:729793.
   PubMed Web of Science ®Google Scholar
• Ornell F, Borelli W, Benzano D, et al. The next pandemic: impact of COVID-19 in mental healthcare assistance in a nationwide epidemiological study. Lancet Reg Health Am. 2021;4:100061.
   PubMedGoogle Scholar
• Chen KL, Brozen M, Rollman JE, et al. How is the COVID-19 pandemic shaping transportation access to health care? Trans Res Interdiscip Perspect. 2021;10:100338.
   PubMedGoogle Scholar
• Nemani K, Li C, Olfson M, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021;78(4):380–386.
   PubMed Web of Science ®Google Scholar
• Suthaharan P, Reed E, Leptourgos P, et al. Paranoia and belief updating during the COVID-19 crisis. Nat Hum Behav. 2021;5(9):1190–1202.
   PubMed Web of Science ®Google Scholar
• Smith CM, Gilbert EB, Riordan PA, et al. COVID-19-associated psychosis: a systematic review of case reports. Gen Hosp Psychiatry. 2021;73:84–100.
   PubMedGoogle Scholar
• Strauss GP, Macdonald KI, Ruiz I, et al. The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2022;272(1):17–27.
   PubMed Web of Science ®Google Scholar
• Fleischmann E, Dalkner N, Fellendorf FT, et al. Psychological impact of the COVID-19 pandemic on individuals with serious mental disorders: a systematic review of the literature. World J Psychiatry. 2021;11(12):1387–1406.
   PubMed Web of Science ®Google Scholar
• Vita A, Minelli A, Barlati S, et al. Treatment-resistant schizophrenia: genetic and neuroimaging correlates. Front Pharmacol. 2019;10:402.
   PubMed Web of Science ®Google Scholar
• González-Ortega I, Vega P, Echeburúa E, et al. A multicentre, randomised, controlled trial of a combined clinical treatment for first-episode psychosis. Int J Environ Res Public Health. 2021;18(14):7239.
   PubMed Web of Science ®Google Scholar
• Brockman R, Kiernan M, Brakoulias V, et al. The relationship between cognitive behavioural therapy maintenance processes, emotional distress, and positive psychotic symptoms: evidence that CBT is "not a Quasi-Neuroleptic.” J Cogn Psychother. 2014;28(2):101–116.
   PubMedGoogle Scholar
• Thomas N, Hayward M, Peters E, et al. Psychological therapies for auditory hallucinations (voices): current status and key directions for future research. Schizophr Bull. 2014;40(4):S202–S212.
   PubMedGoogle Scholar
• Bisso E, Signorelli MS, Milazzo M, et al. Immersive virtual reality applications in schizophrenia spectrum therapy: a systematic review. Int J Environ Res Public Health. 2020;17(17):6111.
   PubMed Web of Science ®Google Scholar
• Craig TK, Rus-Calafell M, Ward T, et al. AVATAR therapy for auditory verbal hallucinations in people with psychosis: a single-blind, randomised controlled trial [published correction appears in lancet psychiatry. 2017 nov 29]. Lancet Psychiatry. 2018;5(1):31–40.
   PubMed Web of Science ®Google Scholar
• Dellazizzo L, Potvin S, Phraxayavong K, et al. One-year randomized trial comparing virtual reality-assisted therapy to cognitive-behavioural therapy for patients with treatment-resistant schizophrenia. NPJ Schizophr. 2021;7(1):9.
   PubMed Web of Science ®Google Scholar
• Kotlarska K, Wielgus B, Cichocki Ł. Phenomenology of the COVID-19 pandemic experience in patients suffering from chronic Schizophrenia-A qualitative analysis. Int J Environ Res Public Health. 2021;19(1):56.
   PubMed Web of Science ®Google Scholar
• van Dis EAM, van Veen SC, Hagenaars MA, et al. Long-term outcomes of cognitive behavioural therapy for Anxiety-Related disorders: a systematic review and meta-analysis [published correction appears in JAMA psychiatry. 2020 jul 1;77(7):768]. JAMA Psychiatry. 2020;77(3):265–273.
   PubMed Web of Science ®Google Scholar
• du Sert OP, Potvin S, Lipp O, et al. Virtual reality therapy for refractory auditory verbal hallucinations in schizophrenia: a pilot clinical trial. Schizophr Res. 2018;197:176–181.
   PubMed Web of Science ®Google Scholar
• Chun Tie Y, Birks M, Francis K. Grounded theory research: a design framework for novice researchers. SAGE Open Med. 2019;7:2050312118822927.
   Web of Science ®Google Scholar
• Chomczynski P. QDA MINER – the mixed method solution for qualitative analysis by provalis research. QSR. 2008;4(2):126–129.
   Google Scholar
• Scott’s Pi. The SAGE encyclopedia of communication research methods. Thousand Oaks (CA): SAGE Publications; 2017.
   Google Scholar
• Dellazizzo L, Potvin S, Phraxayavong K, et al. Exploring the benefits of virtual Reality-Assisted therapy following Cognitive-Behavioural therapy for auditory hallucinations in patients with Treatment-Resistant schizophrenia: a proof of concept. J Clin Med. 2020;9(10):3169.
   PubMed Web of Science ®Google Scholar
• Rathod S, Phiri P, Kingdon D. Cognitive behavioural therapy for schizophrenia. Psychiatr Clin North Am. 2010;33(3):527–536.
   PubMed Web of Science ®Google Scholar
• Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21.
   PubMed Web of Science ®Google Scholar
• Gobbi S, Płomecka M, Ashraf Z, et al. Worsening of preexisting psychiatric conditions during the COVID-19 pandemic. Front Psychiatry. 2020;11:581426.
   PubMed Web of Science ®Google Scholar
• Puangsri P, Jinanarong V, Wattanapisit A. Impacts on and care of psychiatric patients during the outbreak of COVID-19. Clin Pract Epidemiol Ment Health. 2021;17:52–60.
   PubMedGoogle Scholar
• Peters E, Crombie T, Agbedjro D, et al. The long-term effectiveness of cognitive behavior therapy for psychosis within a routine psychological therapies service. Front Psychol. 2015;6:1658.
   PubMed Web of Science ®Google Scholar
• Sivec HJ, Montesano VL. Cognitive behavioural therapy for psychosis in clinical practice. Psychotherapy (Chic). 2012;49(2):258–270.
   PubMed Web of Science ®Google Scholar
• Aali G, Kariotis T, Shokraneh F. Avatar therapy for people with schizophrenia or related disorders. Cochrane Database Syst Rev. 2020;5(5):CD011898.
   PubMedGoogle Scholar
• Kocur M, Dechant M, Wolff C, et al. Computer-Assisted Avatar-Based treatment for dysfunctional beliefs in depressive inpatients: a pilot study. Front Psychiatry. 2021;12:608997.
   PubMed Web of Science ®Google Scholar
• Vallecillo G, Perelló R, Güerri R, et al. Clinical impact of COVID-19 on people with substance use disorders. J Public Health (Oxf). 2021;43(1):9–12.
   PubMed Web of Science ®Google Scholar
• Ornell F, Moura HF, Scherer JN, et al. The COVID-19 pandemic and its impact on sub-stance use: Implications for prevention and treatment. Psychiatry Res. 2020;289:113096.
   PubMed Web of Science ®Google Scholar
• Correll C, Chepke C, Gionfriddo P, et al. The post COVID-19 healthcare landscape and the use of long-acting injectable an-tipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. BMC Psychiatry. 2022;22(1):32.
   PubMed Web of Science ®Google Scholar